Sudarshan Hebbar - 25 Jun 2026 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: Chief Medical Officer
Issuer ticker: CALC
Reported as of: 25 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jun 2026, 08:45:10 UTC
Prior SEC filing: 07 Apr 2026
Next SEC filing: 21 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ John Dunn, Esq., Attorney-in-Fact

Key filing fact

Sudarshan Hebbar filed Form 4 for CalciMedica, Inc. (CALC) on 29 Jun 2026.

Key facts

This page summarizes Sudarshan Hebbar's Form 4 filing for CalciMedica, Inc. (CALC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Jun 2026, 08:45.

Change

Previous filing in this sequence was filed on 07 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001968793 Primary reporting owner

Hebbar Sudarshan

Relationship: Chief Medical Officer
Address: C/O CALCIMEDICA, INC., 505 COAST S. BLVD. #307, LA JOLLA
Signature: /s/ John Dunn, Esq., Attorney-in-Fact
Signature date: 29 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CALC transaction

Common Stock

Award

Transaction value
Shares: +124,486
Change %: +202%
Price: $0.8033^*
Shares after: 186,025
Date: 25 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.